Interim reports

All years

FRISQ’s Interim Report Q2, 2021

CEO Statement FRISQ’s Capital Markets Day in May was a great opportunity to present where we are and where we are moving to. We could then, and can now, report that higher recurring revenues have had a positive effect on cash flow, along with a cost control that has shifted funds from administration to development and commercialization. That shift also includes increasing sales staff and expanding footprints in the UK. We were then also able to present our innovative work with the platform; how w...

Interim Report Q1, 2021 – Turnover exceeding previous full year

CEO Statement The pandemic continues to affect our industry in many ways. But although the room for long-term digitalisation decisions is small right now, FRISQ’s pilot projects continue to run as planned or better. Our clients’ innovation continue to depend heavily on FRISQ Care and we have in several instances been asked to increase our involvement. The feedback from care professionals on our ongoing product developments, is very encouraging. The burden of administrative tasks is reduced, pat...

Report Q4 and Full Year 2020

January-December 2020

Interim Report Q3, 2020

CEO Statement As we’re closing a busy quarter for FRISQ I’m proud to say we’ve carried out a fully subscribed, directed share issue of 78.75 million SEK. This capital infusion will strengthen our sales and implementation efforts in 2021. While we work hard to develop a product that drives both better health outcomes and patient engagement, we are humbly aware that the health care system continues to be under extreme pressure due to the ongoing pandemic, resources are scarce and there’s little energy ...

Interim Report Q2, 2020

CEO statement It is a privilege for me today to present my first quarter and FRISQ’s second quarterly results for 2020.  The ongoing pandemic has presented great challenges for a healthcare sector that, by necessity, has been forced to prioritize emergency care – repeatedly straining old-fashioned tools and methods to, and beyond, the limit – over improvements and digitalization. However, that also makes FRISQ that more relevant. Covid-19 has accelerated and accentuated the need as well as opport...

Interim Report Q1, 2020

Federal stamp of approval creates opportunities in a turbulent time. FRISQ – the only digital solution that meets the requirements for the patient contract

Year-end report 2019

Financial summary fourth quarter 2019 Reported net revenue was 0.03 MSEK (2.6) Net revenue for the quarter was 0.53 MSEK Reclassification of EU financed commercially based projects to Other Income was 0.5 MSEK. Other revenue amounted to 0.6 MSEK (0.4) Earnings per share amounted to -0.9 SEK (-0.7) Cash-flow amounted to -21.0 MSEK (-10.6) Cash and cash equivalent on December 31, was 26.7 MSEK (41.7) Financial summary full year 2019 Reported net revenue was 1.9 MSEK (5.2) Other revenue amounted to...

Interim Report July – September 2019

Continued focus on bigger ventures FRISQ develops globally scalable digital tools for interactive communication between different players within the healthcare chain. Our products facilitate and streamline the work of healthcare professionals and give patients new opportunities to get involved in their own care.

Year-end report 2018 – Strong revenue growth and international launch

Financial development Q4 2018 Total revenue amounted to SEK 3.0 million (0.1), of which net sales amounted to SEK 2.6 million (0.1). Earnings per share amounted to SEK -0.7 (-0.4). January – December 2018 Total revenue amounted to SEK 6.4 million (0.3), of which net sales amounted to SEK 5.3 million (0.2). Earnings per share amounted to SEK -2.2 (-1.5). Cash and cash equivalents as per Dec 31st were SEK 41.9 million (42.5). CEO Martin Irding comments on the year and quarter Strong demand On several o...

Interim Report third quarter 2017

January - September 2017 Financial development third quarter 2017 - Net sales for the quarter amounted to SEK 0.04 million (0). The operating profit for the quarter amounted to SEK -8.1 million (-6.2). Earnings per share for the quarter amounted to SEK -0.4 (-0.3)

Interim Report second quarter 2017

January - June 2017. Financial development second quarter 2017 - Net sales for the quarter amounted to SEK 0.1 million (0). The operating profit for the quarter amounted to SEK -7,7 million (-6.5). Earnings per share for the quarter amounted to SEK -0.4 (-0.4)

Interim Report first quarter 2017

January - March 2017. Financial development first quarter 2017 - The operating profit for the quarter amounted to SEK -7,2 million (-4.9). Earnings per share for the quarter amounted to SEK -0.4 (-0.3)

Year-end report 2016

January – December 2016 Financial development fourth quarter 2016 - Profit after net financial for the quarter amounted to SEK -3.9 million (-5.1). Earnings per share for the quarter amounted to SEK -0.2 (-0.7). Development costs for the quarter amounted to SEK 1.7 million (5.0)